Cara Therapeutics initiated with an Overweight at Cantor Fitzgerald. Cantor Fitzgerald analyst Charles Duncan last night initiated coverage of Cara Therapeutics with an Overweight rating and $27 price target. The analyst, who started coverage on seven Neuro-Innovator and Platform-Enabled Therapeutic companies, believes that “biotech has entered a golden age of innovation and productivity across many therapeutic areas.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.